A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234
Recruiting now · Phase 1
Conditions studied: Healthy Participants
In brief
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of AZD6234. This study will take place at one site in Nottingham, United Kingdom, and will enrol 21 healthy men and women aged 18-55 years.
Key facts
- Study ID
- NCT07220954
- Run by
- AstraZeneca
- People needed
- 21
- Starts
- 2025-11-11
- Expected to finish
- 2027-04-01
- Last updated by the study team
- 2026-05-18
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Healthy males or non-pregnant, non-lactating females aged 18 to 55 years inclusive
- BMI of 25.0 to 35.0 kg/m2 inclusive and weight ≥50 kg
You may not qualify if…
- History of any clinically important disease or disorder
- History or presence of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, neurological, psychiatric or gastrointestinal disorder including a history of pancreatitis or gall stones
- Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the planned first dosing day
- Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis
- Any clinically significant abnormal findings in vital signs
- Any clinically significant abnormalities on 12-lead ECG
- HbA1c ≥6.5% (≥48 mmol/mol)
- Evidence of renal impairment
- Females who are pregnant or lactating.
- Any participant who has received an amylin analogue containing preparation within the last 30 days or 5 half-lives of the drug (whichever is longer)
- Participants who report to have previously received AZD6234.
- Use of any prescribed or non-prescribed medication
Where it is running
- Research Site — Ruddington, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.